A group of investors including Venrock Healthcare Capital Partners, Citadel’s Surveyor Capital unit and Valiant Capital Management invested nearly $72 million in Humanigen in a so-called private investment in public equity, or PIPE deal, announced June 2. Mr. Durrant said the capital is meant in part to build capacity for lenzilumab production in the event it receives approval from the FDA.